Arypsa (APYI) Stock Price
Arypsa Price
Over the last 19 years Arypsa grew revenue by 4.6% annually, reaching 8.53 M USD. Earnings per share have declined at 4.5% per year over the last 13 years. For Arypsa, the net margin of -60.9% is down versus -11.0% a few years ago.
Arypsa stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Arypsa over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Arypsa stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Arypsa's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Arypsa Price |
|---|---|
| 9/14/2026 | 0.00 USD |
| 9/11/2026 | 0.00 USD |
| 9/10/2026 | 0.00 USD |
| 9/9/2026 | 0.00 USD |
| 9/8/2026 | 0.00 USD |
| 9/4/2026 | 0.00 USD |
| 9/3/2026 | 0.00 USD |
| 9/2/2026 | 0.00 USD |
| 9/1/2026 | 0.00 USD |
| 8/31/2026 | 0.00 USD |
| 8/28/2026 | 0.00 USD |
| 8/27/2026 | 0.00 USD |
| 8/26/2026 | 0.00 USD |
| 8/25/2026 | 0.00 USD |
| 8/24/2026 | 0.00 USD |
| 8/21/2026 | 0.00 USD |
| 8/20/2026 | 0.00 USD |
| 8/19/2026 | 0.00 USD |
| 8/18/2026 | 0.00 USD |
| 8/17/2026 | 0.00 USD |
| 8/14/2026 | 0.00 USD |
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
Arypsa Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Arypsa Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESk |
| 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009e | 2010e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 6.00 | 7.00 | 6.00 | 8.00 | 7.00 | 5.00 | 7.00 | 7.00 | 2.00 | 7.00 | 12.00 | 10.00 | 8.00 | – | – |
| – | 20.00 | 16.67 | -14.29 | 33.33 | -12.50 | -28.57 | 40.00 | – | -71.43 | 250.00 | 71.43 | -16.67 | -20.00 | – | – |
| 40.00 | 50.00 | 42.86 | 33.33 | 50.00 | 42.86 | 40.00 | 57.14 | 42.86 | 50.00 | 42.86 | 41.67 | 40.00 | 37.50 | – | – |
| 2.00 | 3.00 | 3.00 | 2.00 | 4.00 | 3.00 | 2.00 | 4.00 | 3.00 | 1.00 | 3.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 |
| – | – | – | 1.00 | – | – | – | – | – | – | 1.00 | 3.00 | 4.00 | 4.00 | – | – |
| – | – | – | 16.67 | – | – | – | – | – | – | 14.29 | 25.00 | 40.00 | 50.00 | – | – |
| – | 1.00 | – | – | – | – | – | – | – | – | -2.00 | -3.00 | -4.00 | -5.00 | – | – |
| – | – | – | – | – | – | – | – | – | – | – | 50.00 | 33.33 | 25.00 | – | – |
| 33.00 | 24.80 | 29.70 | 29.70 | 35.00 | 31.40 | 32.00 | 35.10 | 33.80 | 32.90 | 58.90 | 106.80 | 123.10 | 123.10 | 123.10 | 123.10 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Arypsa generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Arypsa retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Arypsa's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Arypsa has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Arypsa's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Arypsa stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Arypsa Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Arypsa business model & stock analysis
Arypsa SWOT Analysis
Strengths
- Aspyra Inc has a strong track record of providing cutting-edge software solutions in the medical imaging and telemedicine industry.
- The company has an experienced and knowledgeable team that excels in developing innovative technologies and delivering exceptional customer service.
- Aspyra Inc possesses advanced expertise in integrating its software with a wide range of medical devices and systems, enhancing its overall value proposition.
Weaknesses
- One of the primary weaknesses of Aspyra Inc is its heavy dependency on a limited number of key clients, making the company vulnerable to any potential loss of those clients.
- Aspyra Inc may have limitations in terms of its financial resources, potentially limiting its ability to invest in research and development or expand its operations.
- The company may face challenges in quickly adapting to rapidly evolving technology trends and industry standards.
Opportunities
- The growing demand for medical imaging and telemedicine solutions presents a significant opportunity for Aspyra Inc to expand its market presence and generate higher revenues.
- Aspyra Inc can explore strategic partnerships with other healthcare technology companies to leverage synergies and enhance its product offerings.
- The increasing adoption of cloud-based solutions within the healthcare industry opens doors for Aspyra Inc to develop and offer scalable and secure cloud-based platforms.
Threats
- Aspyra Inc faces intense competition from well-established players in the medical imaging and software industry, which may pose a threat to its market share.
- Changing regulatory requirements and compliance standards in the healthcare industry can create challenges for Aspyra Inc in terms of ensuring its software remains up-to-date and compliant.
- Economic downturns or volatility within the healthcare sector could potentially impact customer spending and reduce demand for Aspyra Inc's solutions.
Arypsa Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Arypsa historical P/E ratio, EBIT multiple, and P/S ratio
Arypsa annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Arypsa's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Arypsa's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Arypsa's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Arypsa shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Arypsa stock splits
Since 1991, a total of 0.0019801980198019802 shares have been converted from one Arypsa share.
Arypsa Executives and Management Board
7 members · avg. age 53 · 14 % women
Ademola Lawal (35)
Chief Executive Officer, Chief Operating Officer, Director · since 2008
137,215.00 USD
Management
Marina Varela (39)
Chief Accounting Officer, Corporate Secretary
Board of Directors
Mr. James Zierick (54)
Chairman of the Board · since 2007
Jeffrey Tumbleson (43)
Director
Norman Cohen (74)
Independent Director
Mr. Robert Fogerson (58)
Independent Director
Mr. Lawrence Schmid (69)
Independent Director
Frequently asked questions about Arypsa
Aspyra Inc's business model revolves around providing innovative information technology solutions and services to healthcare organizations. As a leading provider of healthcare IT solutions, Aspyra offers a comprehensive range of products and services including laboratory information systems, picture archiving and communication systems, and revenue cycle management solutions. With a focus on enhancing efficiency, productivity, and patient care, Aspyra aims to streamline workflow processes, integrate data, and improve overall operational performance for its clients in the healthcare industry. Through its advanced technology solutions, Aspyra Inc aims to empower healthcare providers in delivering high-quality care and optimizing their business processes.
Aspyra Inc is primarily active in the healthcare industry.
The main competitors of Aspyra Inc in the market include companies such as Sectra AB, McKesson Corporation, Cerner Corporation, and Agfa-Gevaert Group.
Aspyra Inc is a renowned company with a rich history and background. Established in [year], Aspyra has evolved into a leading player in the [industry]. The company has gained recognition for its innovative [products/services] and commitment to excellence. With a dedicated team of professionals, Aspyra has successfully catered to the needs of its client base, providing cutting-edge solutions and delivering exceptional results. Throughout the years, Aspyra Inc has embraced technological advancements, adapted to market demands, and solidified its position as a trusted industry leader. Their continued success and dedication to quality make Aspyra Inc a prominent player in the market today.
Aspyra Inc, a leading company in the stock market, has achieved noteworthy milestones in its journey. Over the years, Aspyra Inc has successfully expanded its product portfolio, providing innovative solutions to its clients. The company's robust growth strategy has allowed it to establish a strong presence in the market, attracting a wide range of investors. Aspyra Inc has also demonstrated consistent financial performance, augmenting shareholder value and fostering long-term partnerships. With its commitment to excellence and customer satisfaction, Aspyra Inc has positioned itself as a trusted and reliable player in the industry.
Aspyra Inc is primarily present in the United States.
Aspyra Inc is a company that values innovation, integrity, and customer satisfaction. With a strong corporate philosophy focused on delivering cutting-edge solutions, Aspyra Inc strives to meet the diverse needs of its clients. By placing a high emphasis on technology and staying ahead of industry trends, Aspyra Inc ensures that it remains a leader in its field. Aspyra Inc's commitment to providing exceptional products and services is unwavering, making it a trusted choice for businesses seeking reliable solutions. Embracing a customer-centric approach, Aspyra Inc aims to create long-standing partnerships built on trust and collaboration.
Converted at the current exchange rate, the Arypsa share trades at 0.00 EUR (0.00 USD).
Aspyra Inc is a leading company in the field of medical imaging and information management solutions. The company was founded in 2002 and is headquartered in California, USA. Aspyra offers a wide range of solutions for clinics, hospitals, and healthcare centers. The company is divided into two main divisions: 1. Medical Imaging Division In the Medical Imaging division, Aspyra offers various products for disease diagnostics. These include PACS (Picture Archiving and Communication System), mammography information systems, radiology information systems, cardiology information systems, and digital pathology systems. These products facilitate diagnostics and ensure fast and effective communication between specialists. 2. Information Management Division In the Information Management division, Aspyra offers solutions for the healthcare industry. These include electronic patient records, appointment management systems for medical practices, hospital information systems, and prescription management systems. These products help healthcare organizations optimize their internal processes and reduce costs. Aspyra has been around for some time and has built a good reputation. The company works closely with leading experts in the medical field to ensure that its products and services meet the latest standards. Aspyra aims to offer the highest quality in medical imaging and information management solutions. Over the years, the company has also gained a good reputation in customer service and support, as well as in the maintenance and repair of software and hardware. Aspyra has a wide range of customers covering the entire healthcare sector. This includes hospitals, clinics, radiology centers, outpatient surgery centers, and healthcare centers. Aspyra has a strong dealer network that helps position the company in the market. In summary, Aspyra's business model is a product and services company in the field of medical imaging and information management solutions. The company is divided into two main divisions, offering a variety of products and services for healthcare organizations. With its broad customer base and focus on innovation and the highest quality standards, Aspyra has earned its place among the leading providers in the industry.
The revenue cannot currently be calculated for Arypsa.
The profit cannot currently be calculated for Arypsa.
The P/E ratio cannot be calculated for Arypsa at the moment.
The P/S cannot be calculated for Arypsa currently.
The Eulerpool Quality Score for Arypsa is 4/10.
The ISIN of Arypsa is US04538V2034. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Arypsa is APYI. The ticker symbol is used to trade Arypsa shares on the stock exchange.
Arypsa paid dividends every year for the past 0 years.
Arypsa is assigned to the 'Health' sector.
The dividends of Arypsa are distributed in USD.
Arypsa stock
Arypsa Peer Group
Arypsa FIGI
All fundamentals and in-depth analysis of Arypsa
Our stock analysis for Arypsa stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arypsa. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.